Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, ...

A Kingston, Ont., resident says he's finally getting the treatment he needs for a rare cancer he was diagnosed with since the ...

This fashion show fundraiser has provided tens of thousands of dollars to children with cancer. Now it's growing bigger than ...

Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in ...

Study investigates the expression of influenza A virus (IAV) receptors in bovine respiratory, cerebral, and mammary tissues, ...

Extending the use of a continuous positive airway pressure (CPAP) treatment in premature infants by two weeks significantly ...

Aileron Therapeutics (NASDAQ: ALRN) is a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significa ...

Study authors say that the results can help clinicians determine an appropriate length of treatment. Dr. Cindy McEvoy will present “Increased Alveolar Volume and Lung Diffusion Capacity in Former ...

Recently published research paper discusses the significance of reduced end-expiratory lung volume (EELV) in mechanically ventilated patients and its association with increased risk ...

Kronos Bio, Inc.'s drug discovery platform shows potential in targeting transcription regulatory networks. KRON has catalysts as soon as June, click for more.

According to a new report published by Allied Market Research, titled, “Lung Injury Market by Application, Technology, and end user: global opportunity analysis and industry forecast, 2021–2030,” the ...

Includes initial funding of approximately $20 million, as well as the potential for additional proceeds of approximately $20 million from exercise of three-year warrants issued in offeringAUSTIN, ...